Working with TipRanks
Follow Us
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
RESEARCH TOOLSreports
Ultragenyx Pharmaceutical (RARE) Stock Price & Analysis
421 Followers
RARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$32.01 - $54.98
Previous Close$36.83
Volume2.63M
Average Volume (3M)701.99K
Market Cap
$2.63B
Enterprise Value$2.08B
Total Cash (Recent Filing)$551.98M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)-3.6
Beta0.74
Next Earnings
Oct 31, 2023EPS Estimate
-$2.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.25
Shares Outstanding71,488,598
10 Day Avg. Volume1,196,997
30 Day Avg. Volume701,990
Standard Deviation0.15
R-Squared0.09
Alpha-0.00780
Financial Highlights & Ratios
Price to Book (P/B)-32.60
Price to Sales (P/S)56.83
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.10
Enterprise Value/Gross Profit6.50
Enterprise Value/Ebitda-2.90
Forecast
1Y Price Target
$92.93Price Target Upside192.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Ultragenyx Pharmaceutical News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Insights
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $32.01 and its highest was $54.98 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Currently, no data Available
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Oct 31, 2023 which is in 12 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on Aug 03, 2023. The company reported -$2.25 earnings per share for the quarter, missing the consensus estimate of -$2.09 by -$0.16.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -$2.06.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 71,488,600 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$2.25 in its last earnings report, missing expectations of -$2.09. Following the earnings report the stock price went down -8.789%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Among the largest hedge funds holding Ultragenyx Pharmaceutical’s share is Sands Capital Management LLC. It holds Ultragenyx Pharmaceutical’s shares valued at 123M.
---
Ultragenyx Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.93 (192.88% Upside)
$92.93 (192.88% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 75%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $319.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.83%
12-Months-Change
Fundamentals
Return on Equity
-178.60%
Trailing 12-Months
Asset Growth
-0.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
---
Top 5 ETFs holding RARE
Vanguard Total Stock Market ETF
$74.85M
Vanguard Health Care ETF
$8.73M
Vanguard Russell 1000 Growth ETF
$1.95M
Vanguard Russell 1000 ETF
$336.61K
Vanguard Russell 3000 ETF
$154.37K
Up to five ETFs with an Outperform Smart Score that hold RARE. The ETFs are listed according to market value of RARE within the ETF
---